9 reports of this reaction
1.5% of all FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE reports
#15 most reported adverse reaction
DYSGEUSIA is the #15 most commonly reported adverse reaction for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE, manufactured by HyVee Inc. There are 9 FDA adverse event reports linking FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE to DYSGEUSIA. This represents approximately 1.5% of all 604 adverse event reports for this drug.
Patients taking FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE who experience dysgeusia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSGEUSIA is a less commonly reported adverse event for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE, but still significant enough to appear in the safety profile.
In addition to dysgeusia, the following adverse reactions have been reported for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE:
The following drugs have also been linked to dysgeusia in FDA adverse event reports:
DYSGEUSIA has been reported as an adverse event in 9 FDA reports for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSGEUSIA accounts for approximately 1.5% of all adverse event reports for FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE, making it a notable side effect.
If you experience dysgeusia while taking FAMOTIDINE, CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.